Exploring the Next Frontier in Non–Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer. October 26, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.02086 Journal of Clinical Oncology - published online before print November 3, 2022 PMID: 36331252 Exploring the Next Frontier in Non–Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor Martin Sattler , PhD1,2xMartin SattlerSearch for articles by this author and Ravi Salgia , MD, PhD3xRavi SalgiaSearch for articles by this author Show More 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA2Department of Medicine, Harvard Medical School, Boston, MA3Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA https://doi.org/10.1200/JCO.22.02086 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTExploring the Next Frontier in Non–Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor ReceptorThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Ravi SalgiaConsulting or Advisory Role: Iovance Biotherapeutics, AbbVie, Novartis, AstraZenecaSpeakers' Bureau: AstraZeneca, MerckNo other potential conflicts of interest were reported. Companion Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer